SCHEMBL9907372

SCHEMBL9907372

O=C(O)c1ccc2nccc(-c3cc(Cl)ccc3F)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.48
KMO O15229 2/20 0.43
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
MRGPRX4 Q96LA9 2/20 0.41
TTR P02766 2/20 0.41
CDH1 P12830 1/20 0.41
APC P25054 1/20 0.41
CTNNB1 P35222 1/20 0.41
TCF7L2 Q9NQB0 1/20 0.41
SRD5A1 P18405 1/20 0.40
SRD5A2 P31213 1/20 0.40
NR4A2 P43354 1/20 0.40
MAPT P10636 1/20 0.39
CSNK2A1 P68400 2/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
EIF4EBP1 Q13541 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907352 0.91 KMO (0.51) MAPKAPK2KMOCSNK2A2CSNK2BMRGPRX4
SCHEMBL9907362 0.88 MAPKAPK2 (0.49) MAPKAPK2KMOCSNK2A2CSNK2BTTR
SCHEMBL9907370 0.86 MAPKAPK2 (0.40) MAPKAPK2KMOCSNK2A2CSNK2BMRGPRX4
SCHEMBL9907342 0.85 SRD5A2 (0.49) MAPKAPK2CSNK2A2CSNK2BMRGPRX4TTR
SCHEMBL9907348 0.85 MAPKAPK2 (0.44) MAPKAPK2KMOCSNK2A2CSNK2BTTR
SCHEMBL9907369 0.85 HTT (0.46) MAPKAPK2CSNK2A2CSNK2BMAPTCSNK2A1
SCHEMBL9907390 0.84 PTGDR2 (0.45) SRD5A2CSNK2A1PTGFRPTGER1
SCHEMBL9907804 0.83 HTR5A (0.54)
SCHEMBL9907470 0.82 CSNK2A2 (0.41) MAPKAPK2KMOCSNK2A2CSNK2BTTR
SCHEMBL9907478 0.81 HTR5A (0.41) MAPKAPK2KMONR4A2KDM5AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E MAPKAPK2 4333/4885KMO 559/4885CSNK2A2 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.